Literature DB >> 2422296

Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus.

R D Schrier, G P Rice, M B Oldstone.   

Abstract

Human cytomegalovirus (HCMV) infections are commonly associated with immunosuppression. A direct effect of this virus on lymphocyte functions in vitro, however, has not been shown. We have been investigating the effects of low-passage, fresh isolates of HCMV (cell-free and cell-associated) on natural killer cell (NK) activity and T cell proliferation. Cell-associated, low-passage isolates of HCMV markedly depressed NK activity. Suppression of NK activity was clearly manifested only after seven days of culture and could not be correlated with titer of virus or cell viability. Addition of interferon-alpha (IFN-alpha) but not interleukin-2 (IL-2) partially reconstituted the response, whereas depletion of infected monocytes prevented inhibition of NK-mediated lysis. The effects of cell-free and cell-associated isolates of HCMV on T cell proliferation differed in several respects from suppression of NK activity. Both cell-associated and cell-free isolates of HCMV completely abrogated antigen-specific and mitogen responses. This effect was apparent after only three days of culture with virus and was not reversed by either IFN or IL-2. Cell-associated strain AD169 also induced suppression but to a lesser extent. From observations reported here and other data, we suggest that HCMV can cause direct suppression of lymphocyte functions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422296     DOI: 10.1093/infdis/153.6.1084

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

Review 1.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  Latent cytomegalovirus infection and innate immune function following a 75 km cycling time trial.

Authors:  Emily C P LaVoy; David C Nieman; Dru A Henson; R Andrew Shanely; Amy M Knab; Lynn Cialdella-Kam; Richard J Simpson
Journal:  Eur J Appl Physiol       Date:  2013-08-09       Impact factor: 3.078

Review 3.  Molecular biology and immunology of cytomegalovirus.

Authors:  P D Griffiths; J E Grundy
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

4.  Cytomegalovirus infection of peripheral blood mononuclear cells: effects on interleukin-1 and -2 production and responsiveness.

Authors:  K Kapasi; G P Rice
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

Review 5.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

6.  Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group.

Authors:  R D Schrier; W R Freeman; C A Wiley; J A McCutchan
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Selective impairment of T lymphocyte activation through the T cell receptor/CD3 complex after cytomegalovirus infection.

Authors:  M Timón; A Arnaiz-Villena; J Ruiz-Contreras; J T Ramos-Amador; A Pacheco; J R Regueiro
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

8.  Priming of immature thymocytes to CD3-mediated apoptosis by infection with murine cytomegalovirus.

Authors:  Y Koga; K Tanaka; Y Y Lu; M Oh-Tsu; M Sasaki; G Kimura; K Nomoto
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  A case of Aspergillus fumigatus peritonitis complicating liver transplantation.

Authors:  J S Sartin; M P Wilhelm; M R Keating; K Batts; R A Krom
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

10.  Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation.

Authors:  G J Boland; R J Hene; C Ververs; M A de Haan; G C de Gast
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.